DR. DAVID R WALLACE, M.D.
Radiology in San Diego, CA
License number
California A136122
Category
Radiology
Type
Diagnostic Radiology
License number
California MD.204718
Category
Radiology
Type
Diagnostic Radiology
Address
Address
200 W Arbor Dr #, San Diego, CA 92102
Phone
(619) 543-622x
Personal information
See more information about DAVID R WALLACE at radaris.comName
Address
Phone
500 N Cahuilla Rd APT G, Palm Springs, CA 92262
4 Monet Ct, Rancho Mirage, CA 92270
4949 Garfield St, La Mesa, CA 91941
4924 Londonberry Dr, Santa Rosa, CA 95403
5017 Diamond Heights Blvd, San Francisco, CA 94131
Organization information
See more information about DAVID R WALLACE at bizstanding.comDAVID R WALLACE CPA
PO Box 420459, San Diego, CA 92142
Industry:
Accountant
Phone:
(858) 560-6431 (Phone)
Professional information
See more information about DAVID R WALLACE at trustoria.com
David Wallace
David Wallace
Position:
CEO & General Manager at Senior Helpers - Voted One of the BEST IN SAN DIEGO for 2 Years in a Row, Interim Chair, Board of Directors at San Diego Mayor's Senior Affairs Advisory Board, Vice Chairman, Board of Directors at Glenner Memory Care Centers, Vice President, Board of Directors at Mission Hills Business Improvement District (BID), Member, Board of Directors at ACCION San Diego
Location:
Greater San Diego Area
Industry:
Hospital & Health Care
Work:
Senior Helpers - Voted One of the BEST IN SAN DIEGO for 2 Years in a Row
- Greater San Diego Area since Mar 2008
-
CEO & General Manager
San Diego Mayor's Senior Affairs Advisory Board
- Greater San Diego Area since Nov 2012
-
Interim Chair, Board of Directors
Glenner Memory Care Centers
since Feb 2012
-
Vice Chairman, Board of Directors
Mission Hills Business Improvement District (BID)
- San Diego, CA since May 2010
-
Vice President, Board of Directors
ACCION San Diego
since Oct 2007
-
Member, Board of Directors
Uptown Community Parking District
- Greater San Diego Area Nov 2011 - Mar 2012
-
Member, Board of Directors
Southern Caregiver Resource Center
Sep 2010 - Mar 2012
-
Vice President, Board of Directors
DATASKILL
Apr 2006 - Jan 2008
-
Director of Sales Operations
Data Strategies
Aug 1998 - Mar 2005
-
Director of Sales & Marketing
Wolters-Kluwer / CCH
Jun 1995 - Jul 1998
-
Sales Manager
PVA Systems
Jun 1992 - Jun 1995
-
General Manager
Skills:
Alzheimer's disease, Dementia Care, Seniors, Caregiving, Elder Care, Public Policy, Non-profits, Non-profit Board Development, Parking, Elder Law, Estate Planning, EMR, Physician Practice Management, Practice Management, Veterans, Assisted Living, Home Care, Healthcare, Hospice, Care Management, Small Business Lending, Economic Development, Long Term Care, Long-term Care, Care Planning, Healthcare Management, SaaS, Fundraising, Business Planning, Leadership, Microcredit, Marketing Strategy, Community Outreach, Lead Generation, New Business Development, Strategic Planning, Public Speaking, Strategy, Sales Management, Customer Service, Physicians, Aging in Place, Program Management, Start-ups, Sales, Channel Management
Manager - Premium Accounting At Icw Group
Manager - Premium Accounting At Icw Group
Position:
Manager - Premium Accounting at ICW Group
Location:
Greater San Diego Area
Industry:
Insurance
Work:
ICW Group
since Mar 2013
-
Manager - Premium Accounting
ICW Group
Jun 2008 - Mar 2013
-
Supervisor - Premium Accounting
ICW Group
Oct 2010 - Dec 2011
-
Team Lead
ICW Group
Mar 2006 - May 2008
-
Receivables Representative
Premera Blue Cross
2004 - 2006
-
Membership and Billing Specialist
Education:
Eastern Washington University 1998 - 2002
Bachelor of Arts, Business Administration - Finance
Bachelor of Arts, Business Administration - Finance
Skills:
Insurance, Workers Compensation, Process Improvement, Business Analysis, Business Process Improvement, Business Process, Accounting, Analysis, Business Requirements, Property & Casualty Insurance, Financial Analysis, SAP, Software Documentation, Microsoft Excel, Accounts Receivable
Manager At The Line Printing
Manager At The Line Printing
Position:
manager at The Line Printing
Location:
Greater San Diego Area
Industry:
Printing
Work:
The Line Printing
-
manager
David Brian Wallace, San Diego CA - Lawyer
David Brian Wallace, San Diego CA - Lawyer
Address:
Ofc US Atty/Southern District
880 Front St STE 6293, San Diego 92101
(619) 546-7669
880 Front St STE 6293, San Diego 92101
(619) 546-7669
Licenses:
California - Active 1994
Education:
Pepperdine University School of Law
San Diego State University
San Diego State University
Fragrance And Methods For Production Of 5-Epi-Β-Vetivone, 2-Isopropyl-6,10-Dimethyl-Spiro[4.5]Deca-2,6-Dien-8-One, And 2-Isopropyl-6,10-Dimethyl-Spiro[4.5]Deca-1,6-Dien-8-One
Fragrance And Methods For Production Of 5-Epi-Β-Vetivone, 2-Isopropyl-6,10-Dimethyl-Spiro[4.5]Deca-2,6-Dien-8-One, And 2-Isopropyl-6,10-Dimethyl-Spiro[4.5]Deca-1,6-Dien-8-One
US Patent:
8124811, Feb 28, 2012
Filed:
Oct 14, 2009
Appl. No.:
12/579232
Inventors:
Bryan N. Julien - Lexington KY, US
David M. Wallace - San Diego CA, US
David M. Wallace - San Diego CA, US
Assignee:
Allylix, Inc. - San Diego CA
International Classification:
C07C 49/00, A61K 8/18
US Classification:
568367, 568377, 512 27
Abstract:
The present invention is directed to novel methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4. 5]deca-2,6-dien-8-one and 2-isopropyl-6,10-dimethyl-spiro[4. 5]deca-1,6-dien-8-one, which are useful for their fragrant qualities. In one embodiment the present invention describes a method for production of 5-epi-β-vetivone by the use of premnaspirodiene as starting material. In another embodiment the present invention describes a method for production of 2-isopropyl-6,10-dimethyl-spiro[4. 5]deca-2,6-dien-8-one and 2-isopropyl-6,10-dimethyl-spiro[4. 5]deca-1,6-dien-8-one by the use of premnaspirodiene as starting material. In yet another embodiment the present invention describes a novel method for production of premnaspirodiene from a terpene substrate. Use of the fragrant components or any composition containing the component can be advantageously employed in the perfumery industry.
Fragrance And Methods For Production Of 5-Epi-Β-Vetivone, 2-Isopropyl-6, 10-Dimethyl-Spiro[4.5]Deca-2,6-Dien-8-One, And 2-Isopropyl-6, 10-Dimethyl-Spiro[4.5]Deca-1, 6-Dien-8-One
Fragrance And Methods For Production Of 5-Epi-Β-Vetivone, 2-Isopropyl-6, 10-Dimethyl-Spiro[4.5]Deca-2,6-Dien-8-One, And 2-Isopropyl-6, 10-Dimethyl-Spiro[4.5]Deca-1, 6-Dien-8-One
US Patent:
8642815, Feb 4, 2014
Filed:
Dec 13, 2012
Appl. No.:
13/694597
Inventors:
Bryan N. Julien - Lexington KY, US
David M. Wallace - San Diego CA, US
David M. Wallace - San Diego CA, US
Assignee:
Allylix, Inc. - San Diego CA
International Classification:
C07C 49/00, C07C 2/76, C12P 5/00
US Classification:
568367, 585360, 435166
Abstract:
The present invention is directed to novel methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4. 5]deca-2,6-dien-8-one and 2-isopropyl-6,10-dimethylspiro[4. 5]deca-1,6-dien-8-one, which are useful for their fragrant qualities. Provided are methods for production of premnaspirodiene from a terpene substrate, methods for production of 5-epi-β-vetivone from premnaspirodiene as starting material, and methods for production of 2-isopropyl-6,10-dimethyl-spiro[4. 5]deca-2,6-dien-8-one and 2-isopropyl-6,10-dimethyl-spiro[4. 5]deca-1,6-dien-8-one from premnaspirodiene as starting material.
Indazole Inhibitors Of The Wnt Signal Pathway And Therapeutic Uses Thereof
Indazole Inhibitors Of The Wnt Signal Pathway And Therapeutic Uses Thereof
US Patent:
2014000, Jan 2, 2014
Filed:
Sep 5, 2013
Appl. No.:
14/019103
Inventors:
David Mark Wallace - San Diego CA, US
Sunil Kumar KC - San Diego CA, US
Sunil Kumar KC - San Diego CA, US
Assignee:
Samumed, LLC - San Diego CA
International Classification:
C07D 471/04
US Classification:
514256, 546118, 514303, 544333
Abstract:
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Indazole Inhibitors Of The Wnt Signal Pathway And Therapeutic Uses Thereof
Indazole Inhibitors Of The Wnt Signal Pathway And Therapeutic Uses Thereof
US Patent:
2013004, Feb 14, 2013
Filed:
Jul 18, 2012
Appl. No.:
13/552188
Inventors:
John Hood - San Diego CA, US
David Mark Wallace - San Diego CA, US
Sunil Kumar KC - San Diego CA, US
David Mark Wallace - San Diego CA, US
Sunil Kumar KC - San Diego CA, US
Assignee:
Samumed, LLC - San Diego CA
International Classification:
A61K 31/444, A61K 31/506, A61P 35/00, A61P 27/02, A61P 19/02, A61P 17/06, A61P 31/10, A61P 31/12, A61P 19/08, A61P 19/04, A61P 25/28, A61P 9/00, A61P 3/04, A61P 43/00, A61P 3/10, A61P 15/00, A61P 25/00, A61P 35/02, A61K 31/4545
US Classification:
514275, 514303, 514256
Abstract:
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Coumarin Derivatives Useful As Tnfα Inhibitors
Coumarin Derivatives Useful As Tnfα Inhibitors
US Patent:
7872142, Jan 18, 2011
Filed:
Mar 18, 2010
Appl. No.:
12/726986
Inventors:
Jie Fei Cheng - Carlsbad CA, US
Thomas Arrhenius - Del Mar CA, US
David Wallace - San Diego CA, US
Mi Chen - San Diego CA, US
Sovouthy Tith - San Diego CA, US
Hirotaka Kashiwagi - Shizuoka, JP
Yoshiyuki Ono - Shizuoka, JP
Yoshiaki Watanabe - Tokyo, JP
Thomas Arrhenius - Del Mar CA, US
David Wallace - San Diego CA, US
Mi Chen - San Diego CA, US
Sovouthy Tith - San Diego CA, US
Hirotaka Kashiwagi - Shizuoka, JP
Yoshiyuki Ono - Shizuoka, JP
Yoshiaki Watanabe - Tokyo, JP
Assignee:
Chugai Seiyaku Kabushiki Kaisha - Tokyo
International Classification:
C07D 405/06
US Classification:
5462831, 549289
Abstract:
Novel compounds composition capable of inhibiting TNFα and having antiimmunoinflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
Malonyl-Coa Decarboxylase Inhibitors Useful As Metabolic Modulators
Malonyl-Coa Decarboxylase Inhibitors Useful As Metabolic Modulators
US Patent:
2008007, Mar 20, 2008
Filed:
Sep 14, 2007
Appl. No.:
11/855984
Inventors:
Thomas Arrhenius - Del Mar CA, US
Mi Chen - San Diego CA, US
Jie Fei Cheng - Carlsbad CA, US
Yujin Huang - San Diego CA, US
Alex Nadzan - Encinitas CA, US
Sovouthy Tith - San Diego CA, US
David Wallace - San Diego CA, US
Bin Liu - San Diego CA, US
Masahiro Nishimoto - Shizuoka, JP
Gary Lopaschuk - Edmonton, CA
Jason Dyck - Sherwood Park, CA
Mi Chen - San Diego CA, US
Jie Fei Cheng - Carlsbad CA, US
Yujin Huang - San Diego CA, US
Alex Nadzan - Encinitas CA, US
Sovouthy Tith - San Diego CA, US
David Wallace - San Diego CA, US
Bin Liu - San Diego CA, US
Masahiro Nishimoto - Shizuoka, JP
Gary Lopaschuk - Edmonton, CA
Jason Dyck - Sherwood Park, CA
Assignee:
CHUGAI SEIYAKU KABUSHIKI KAISHA - Tokyo
International Classification:
A61K 31/66, A61K 31/155, A61K 31/185, A61P 3/10, A61P 9/00, A61P 35/00, A61P 3/04, A61K 31/277
US Classification:
514114000, 514237800, 514378000, 514399000, 514406000, 514461000, 514520000, 514553000, 514634000, 514640000, 514675000
Abstract:
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.